Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

BioFocus. (5/12/11). "Press Release: Astellas Pharma and BioFocus Sign Target Discovery Agreement".

Organisations Organisation BioFocus (divsion of Galapagos)
  Group Galapagos (Group)
  Organisation 2 Astellas Pharma Inc. (TSE: 4503)
  Group Astellas (Group)
Products Product SilenceSelect® gene knock-down platform
  Product 2 drug target identification
Person Person Newton, Chris (BioFocus 200808 Senior VP)
     


BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.

"We are delighted to support Astellas Pharma in its research" said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. "Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology".


About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, DM Complications and Metabolic Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.


About BioFocus

BioFocus aims to expand its partners' drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 245 employees in four countries worldwide.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Galapagos (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top